Table 4. Univariate logistic regression analysis with enthesis hypoechogenicity, thickening, enthesophyte, bony irregularity as dependent variables.

	Hypoechogenicity		Thickening		Enthesophyte		Bony irregularity
		P value	O.R.(95% CI)	P value	O.R.(95% CI)	P value	O.R.(95% CI)	P value
	O.R.(95% CI)	P value	O.R.(95% CI)	P value	O.R.(95% CI)	P value	O.R.(95% CI)	P value
Age	1.05 (0.97–1.13)	.20	1.03 (0.96–1.10)	.41	1.01(0.96–1.06)	.77	0.97(0.91–1.02)	.26
Sex	1.56 (0.43–5.72)	.50	1.83(0.51–6.51)	.35	0.80(0.33–1.92)	.62	2.11(0.73–6.12)	.17
T2DM duration	1.06(0.97–1.16)	.21	1.07(0.98–1.17)	.13	1.02(0.96–1.09)	.47	0.94(0.87–1.02)	.15
OADs treated	2.03(0.24–17.04)	.51	1.08(0.95–1.24)	.21	0.59(0.19–1.82)	.36	1.78(0.37–8.57)	.47
Insulin treated	2.25(0.59–8.55)	.23	1.21(0.30–4.92)	.79	0.95(0.33–2.75)	.93	1.34(0.42–4.26)	.61
Statin treated	4.35(0.53–35.7)	.17	4.87(0.60–39.62)	.14	0.96(0.36–2.53)	.94	4.02(0.86–18.70)	.08
Retinopathy	1.94(0.55–6.85)	.30	3.5(0.98–12.5)	.05	5.13(2.0–13.15)	.001	0.64(0.22–1.85)	.41
Macrovascular disease	1.29(0.36–4.54)	.70	0.72(0.20–2.58)	.62	0.50(0.19–1.28)	.15	1.11(0.40–3.07)	.83
Reduced eGFR	0.47(0.13–1.65)	.24	0.84(0.25–2.86)	.78	2.93(1.06–8.10)	.04	0.62(0.23–1.70)	.62
High blood pressure	0.57(0.16–2.0)	.38	1.02(0.30–3.45)	.98	0.95(0.39–2.30)	.91	1.30(0.46–3.66)	.61
BMI	1.00(0.88–1.14)	.99	1.09(0.96–1.22)	.17	1.01(0.92–1.11)	.86	0.87(0.76–0.99)	.05
Mean glucose	1.00(0.99–1.02)	.58	0.99(0.97–1.01)	.39	1.01(1.00–1.03)	.03	1.00(0.99–1.02)	.54
Mean A1c	1.25(0.80–1.95)	.32	0.96(0.61–1.53)	.87	1.27(0.92–1.75)	.15	0.94(0.64–1.38)	.74
Total cholesterol	0.99(0.98–1.02)	.91	1.00(0.99–1.02)	.74	0.99(0.98–1.01)	.25	0.99(0.98–1.00)	.19
LDL-cholesterol	0.99(0.97–1.01)	.44	0.99(0.97–1.01)	.38	0.99(0.98–1.01)	.32	0.98(0.96–1.00)	.02

Legend: T2DM, type 2 diabetes mellitus; OADs, oral antidiabetic drugs; eGFR, estimated glomerular filtration rate; BMI, body mass index; A1c, glycated hemoglobin; LDL, low-density lipoprotein.